Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3242 PWToday Stories

Spot of bother

08 Aug 03

Amgen flying

23 Jul 03

Boehringer oblivious to urge to merge

11 Jul 03

Indepenedent German drug maker Boehringer Ingelheim is to avoid any M&A activity out of concern that it would slow their predicted five years of double digit growth. Boehringer CEO Rolf Krebs said "Any big collaboration, merger or acquisition has the effect of slowing down a company. Most firms involved in M&A have become bigger but less productive." Instead the company intend to drive growth through expansion in the US, which accounted for 44.6% of it's sales in 2002 and through collaborations, the first of which will see the company's smoker's cough drug Spiriva marketed globally by Pfizer. The company is aiming to increase their rep presence in the US to 3000, a giant leap from the 600 employed a couple of years ago. Other manufacturing and collaborative deals with the likes of Eli Lilly and Wyeth should ensure the company can produce effective launches for it's promising pipeline of drugs and achieve their five year growth targets. In the height of the frenzy to consolidate a company still owned by less than twenty of it's founder descendents may have looked destined for obsolescence but sound management and good science will give Boehringer Ingelheim the chance to thrive in the new world of pharma industry druggernauts.

Velcade Victory

01 Jul 03
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.